Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Facts and hypotheses about the programming of neuroplastic deficits by prenatal malnutrition.

Barra R, Morgan C, Sáez-Briones P, Reyes-Parada M, Burgos H, Morales B, Hernández A.

Nutr Rev. 2019 Feb 1;77(2):65-80. doi: 10.1093/nutrit/nuy047.

PMID:
30445479
2.

3D similarities between the binding sites of monoaminergic target proteins.

Núñez-Vivanco G, Fierro A, Moya P, Iturriaga-Vásquez P, Reyes-Parada M.

PLoS One. 2018 Jul 20;13(7):e0200637. doi: 10.1371/journal.pone.0200637. eCollection 2018.

3.

Neonatal programming with testosterone propionate reduces dopamine transporter expression in nucleus accumbens and methylphenidate-induced locomotor activity in adult female rats.

Dib T, Martínez-Pinto J, Reyes-Parada M, Torres GE, Sotomayor-Zárate R.

Behav Brain Res. 2018 Jul 2;346:80-85. doi: 10.1016/j.bbr.2017.12.001. Epub 2017 Dec 6.

PMID:
29221813
4.

Characterization of a Novel Drosophila SERT Mutant: Insights on the Contribution of the Serotonin Neural System to Behaviors.

Hidalgo S, Molina-Mateo D, Escobedo P, Zárate RV, Fritz E, Fierro A, Perez EG, Iturriaga-Vasquez P, Reyes-Parada M, Varas R, Fuenzalida-Uribe N, Campusano JM.

ACS Chem Neurosci. 2017 Oct 18;8(10):2168-2179. doi: 10.1021/acschemneuro.7b00089. Epub 2017 Jul 24.

PMID:
28665105
5.

Synthesis and Docking of Novel 3-Indolylpropyl Derivatives as New Polypharmacological Agents Displaying Affinity for 5-HT1A R/SERT.

Pessoa-Mahana H, Silva-Matus P, Pessoa-Mahana CD, Chung H, Iturriaga-Vásquez P, Quiroz G, Möller-Acuña P, Zapata-Torres G, Saitz-Barría C, Araya-Maturana R, Reyes-Parada M.

Arch Pharm (Weinheim). 2017 Jan;350(1). doi: 10.1002/ardp.201600271. Epub 2016 Dec 16.

PMID:
27981607
6.

The development of novel polypharmacological agents targeting the multiple binding sites of nicotinic acetylcholine receptors.

Reyes-Parada M, Iturriaga-Vasquez P.

Expert Opin Drug Discov. 2016 Oct;11(10):969-81. doi: 10.1080/17460441.2016.1227317. Epub 2016 Aug 30. Review.

PMID:
27552487
7.

Geomfinder: a multi-feature identifier of similar three-dimensional protein patterns: a ligand-independent approach.

Núñez-Vivanco G, Valdés-Jiménez A, Besoaín F, Reyes-Parada M.

J Cheminform. 2016 Apr 18;8:19. doi: 10.1186/s13321-016-0131-9. eCollection 2016.

8.

Multiple binding sites in the nicotinic acetylcholine receptors: An opportunity for polypharmacolgy.

Iturriaga-Vásquez P, Alzate-Morales J, Bermudez I, Varas R, Reyes-Parada M.

Pharmacol Res. 2015 Nov;101:9-17. doi: 10.1016/j.phrs.2015.08.018. Epub 2015 Aug 28. Review.

PMID:
26318763
9.

Similarities between the Binding Sites of SB-206553 at Serotonin Type 2 and Alpha7 Acetylcholine Nicotinic Receptors: Rationale for Its Polypharmacological Profile.

Möller-Acuña P, Contreras-Riquelme JS, Rojas-Fuentes C, Nuñez-Vivanco G, Alzate-Morales J, Iturriaga-Vásquez P, Arias HR, Reyes-Parada M.

PLoS One. 2015 Aug 5;10(8):e0134444. doi: 10.1371/journal.pone.0134444. eCollection 2015.

10.

Synthesis, Biological Evaluation, and Molecular Simulation of Chalcones and Aurones as Selective MAO-B Inhibitors.

Morales-Camilo N, Salas CO, Sanhueza C, Espinosa-Bustos C, Sepúlveda-Boza S, Reyes-Parada M, Gonzalez-Nilo F, Caroli-Rezende M, Fierro A.

Chem Biol Drug Des. 2015 Jun;85(6):685-95. doi: 10.1111/cbdd.12458. Epub 2014 Nov 15.

PMID:
25346162
11.

Improving amphetamine therapeutic selectivity: N,N-dimethyl-MTA has dopaminergic effects and does not produce aortic contraction.

Sotomayor-Zárate R, Jara P, Araos P, Vinet R, Quiroz G, Renard GM, Espinosa P, Hurtado-Guzmán C, Moya PR, Iturriaga-Vásquez P, Gysling K, Reyes-Parada M.

Basic Clin Pharmacol Toxicol. 2014 May;114(5):395-9. doi: 10.1111/bcpt.12168. Epub 2013 Dec 7.

12.

Synthesis, docking and pharmacological evaluation of novel homo- and hetero-bis 3-piperazinylpropylindole derivatives at SERT and 5-HT1A receptor.

Pessoa-Mahana H, González-Lira C, Fierro A, Zapata-Torres G, Pessoa-Mahana CD, Ortiz-Severin J, Iturriaga-Vásquez P, Reyes-Parada M, Silva-Matus P, Saitz-Barría C, Araya-Maturana R.

Bioorg Med Chem. 2013 Dec 15;21(24):7604-11. doi: 10.1016/j.bmc.2013.10.036. Epub 2013 Nov 6.

PMID:
24262884
13.

4-Methylthioamphetamine increases dopamine in the rat striatum and has rewarding effects in vivo.

Sotomayor-Zárate R, Quiroz G, Araya KA, Abarca J, Ibáñez MR, Montecinos A, Guajardo C, Núñez G, Fierro A, Moya PR, Iturriaga-Vásquez P, Gómez-Molina C, Gysling K, Reyes-Parada M.

Basic Clin Pharmacol Toxicol. 2012 Dec;111(6):371-9. doi: 10.1111/j.1742-7843.2012.00926.x. Epub 2012 Aug 31.

14.

Synthesis, 5-hydroxytryptamine1A receptor affinity and docking studies of 3-[3-(4-aryl-1-piperazinyl)-propyl]-1H-indole derivatives.

Pessoa-Mahana H, Núñez CU, Araya-Maturana R, Barría CS, Zapata-Torres G, Pessoa-Mahana CD, Iturriaga-Vasquez P, Mella-Raipán J, Reyes-Parada M, Celis-Barros C.

Chem Pharm Bull (Tokyo). 2012;60(5):632-8.

15.

Acutely applied MDMA enhances long-term potentiation in rat hippocampus involving D1/D5 and 5-HT2 receptors through a polysynaptic mechanism.

Rozas C, Loyola S, Ugarte G, Zeise ML, Reyes-Parada M, Pancetti F, Rojas P, Morales B.

Eur Neuropsychopharmacol. 2012 Aug;22(8):584-95. doi: 10.1016/j.euroneuro.2011.11.010. Epub 2011 Dec 29.

PMID:
22209363
16.

2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors.

Lühr S, Vilches-Herrera M, Fierro A, Ramsay RR, Edmondson DE, Reyes-Parada M, Cassels BK, Iturriaga-Vásquez P.

Bioorg Med Chem. 2010 Feb 15;18(4):1388-95. doi: 10.1016/j.bmc.2010.01.029. Epub 2010 Jan 15.

PMID:
20123154
17.

MDMA ("ecstasy") impairs learning in the Morris Water Maze and reduces hippocampal LTP in young rats.

Arias-Cavieres A, Rozas C, Reyes-Parada M, Barrera N, Pancetti F, Loyola S, Lorca RA, Zeise ML, Morales B.

Neurosci Lett. 2010 Jan 29;469(3):375-9. doi: 10.1016/j.neulet.2009.12.031. Epub 2009 Dec 18.

PMID:
20026184
18.

Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors.

Vilches-Herrera M, Miranda-Sepúlveda J, Rebolledo-Fuentes M, Fierro A, Lühr S, Iturriaga-Vasquez P, Cassels BK, Reyes-Parada M.

Bioorg Med Chem. 2009 Mar 15;17(6):2452-60. doi: 10.1016/j.bmc.2009.01.074. Epub 2009 Feb 8.

PMID:
19243954
19.

Prenatal to early postnatal nicotine exposure impairs central chemoreception and modifies breathing pattern in mouse neonates: a probable link to sudden infant death syndrome.

Eugenín J, Otárola M, Bravo E, Coddou C, Cerpa V, Reyes-Parada M, Llona I, von Bernhardi R.

J Neurosci. 2008 Dec 17;28(51):13907-17. doi: 10.1523/JNEUROSCI.4441-08.2008.

20.

N,N-dimethyl-thioamphetamine and methyl-thioamphetamine, two non-neurotoxic substrates of 5-HT transporters, have scant in vitro efficacy for the induction of transporter-mediated 5-HT release and currents.

Gobbi M, Funicello M, Gerstbrein K, Holy M, Moya PR, Sotomayor R, Forray MI, Gysling K, Paluzzi S, Bonanno G, Reyes-Parada M, Sitte HH, Mennini T.

J Neurochem. 2008 Jun;105(5):1770-80. doi: 10.1111/j.1471-4159.2008.05272.x. Epub 2008 Feb 4.

21.

Human and rat monoamine oxidase-A are differentially inhibited by (S)-4-alkylthioamphetamine derivatives: insights from molecular modeling studies.

Fierro A, Osorio-Olivares M, Cassels BK, Edmondson DE, Sepúlveda-Boza S, Reyes-Parada M.

Bioorg Med Chem. 2007 Aug 1;15(15):5198-206. Epub 2007 May 22.

22.

Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors.

Moya PR, Berg KA, Gutiérrez-Hernandez MA, Sáez-Briones P, Reyes-Parada M, Cassels BK, Clarke WP.

J Pharmacol Exp Ther. 2007 Jun;321(3):1054-61. Epub 2007 Mar 2.

PMID:
17337633
23.

Heteroarylisopropylamines as MAO inhibitors.

Vallejos G, Fierro A, Rezende MC, Sepúlveda-Boza S, Reyes-Parada M.

Bioorg Med Chem. 2005 Jul 15;13(14):4450-7.

PMID:
15908219
24.

Sulfur-substituted alpha-alkyl phenethylamines as selective and reversible MAO-A inhibitors: biological activities, CoMFA analysis, and active site modeling.

Gallardo-Godoy A, Fierro A, McLean TH, Castillo M, Cassels BK, Reyes-Parada M, Nichols DE.

J Med Chem. 2005 Apr 7;48(7):2407-19.

PMID:
15801832
25.

Delayed early morning turn "ON" in response to a single dose of levodopa in advanced Parkinson's disease: pharmacokinetics should be considered.

Chaná P, Kuntsmann C, Reyes-Parada M, Sáez-Briones P.

J Neurol Neurosurg Psychiatry. 2004 Dec;75(12):1782-3. No abstract available.

26.

Monoamine oxidase inhibitory properties of optical isomers and N-substituted derivatives of 4-methylthioamphetamine.

Hurtado-Guzmán C, Fierro A, Iturriaga-Vásquez P, Sepúlveda-Boza S, Cassels BK, Reyes-Parada M.

J Enzyme Inhib Med Chem. 2003 Aug;18(4):339-47.

PMID:
14567549
27.

[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study].

Chaná P, Fierro A, Reyes-Parada M, Sáez-Briones P.

Rev Med Chil. 2003 Jun;131(6):623-31. Spanish.

PMID:
12942590
29.

ALEPH-2, a suspected anxiolytic and putative hallucinogenic phenylisopropylamine derivative, is a 5-HT2a and 5-HT2c receptor agonist.

Acuña-Castillo C, Scorza C, Reyes-Parada M, Cassels BK, Huidobro-Toro JP.

Life Sci. 2000 Nov 17;67(26):3241-7.

PMID:
11191631
30.
31.

Dopaminergic pharmacology and antioxidant properties of pukateine, a natural product lead for the design of agents increasing dopamine neurotransmission.

Dajas-Bailador FA, Asencio M, Bonilla C, Scorza MC, Echeverry C, Reyes-Parada M, Silveira R, Protais P, Russell G, Cassels BK, Dajas F.

Gen Pharmacol. 1999 Mar;32(3):373-9.

PMID:
10211594
32.

Effects of the D3 preferring dopamine agonist pramipexole on sleep and waking, locomotor activity and striatal dopamine release in rats.

Lagos P, Scorza C, Monti JM, Jantos H, Reyes-Parada M, Silveira R, Ponzoni A.

Eur Neuropsychopharmacol. 1998 May;8(2):113-20.

PMID:
9619689
33.

Monoamine oxidase inhibitory properties of some methoxylated and alkylthio amphetamine derivatives: structure-activity relationships.

Scorza MC, Carrau C, Silveira R, Zapata-Torres G, Cassels BK, Reyes-Parada M.

Biochem Pharmacol. 1997 Dec 15;54(12):1361-9.

PMID:
9393679
34.

(+/-)-1-(2,5-Dimethoxy-4-ethylthiophenyl)-2-aminopropane (ALEPH-2), a novel putative anxiolytic agent lacking affinity for benzodiazepine sites and serotonin-1A receptors.

Reyes-Parada M, Scorza C, Romero V, Silveira R, Medina JH, Andrus D, Nichols DE, Cassels BK.

Naunyn Schmiedebergs Arch Pharmacol. 1996 Nov;354(5):579-85.

PMID:
8938655
35.

Behavioral effects of the putative anxiolytic (+/-)-1-(2,5-dimethoxy-4-ethylthiophenyl)-2-aminopropane (ALEPH-2) in rats and mice.

Scorza MC, Reyes-Parada M, Silveira R, Viola H, Medina JH, Viana MB, Zangrossi H Jr, Graeff FG.

Pharmacol Biochem Behav. 1996 Jun;54(2):355-61.

PMID:
8743595
36.

Sleep and waking in 5,7-DHT-lesioned or (-)-pindolol-pretreated rats after administration of buspirone, ipsapirone, or gepirone.

Monti JM, Jantos H, Silveira R, Reyes-Parada M, Scorza C.

Pharmacol Biochem Behav. 1995 Oct;52(2):305-12.

PMID:
8577795
37.

Depletion of brain serotonin by 5,7-DHT: effects on the 8-OH-DPAT-induced changes of sleep and waking in the rat.

Monti JM, Jantos H, Silveira R, Reyes-Parada M, Scorza C, Prunell G.

Psychopharmacology (Berl). 1994 Jun;115(1-2):273-7.

PMID:
7532312
38.

Monoamine oxidase inhibitory effects of some 4-aminophenethylamine derivatives.

Reyes-Parada M, Scorza MC, Silveira R, Dajas F, Costa G, Tipton KF, Cassels BK.

Biochem Pharmacol. 1994 Apr 20;47(8):1365-71.

PMID:
7514408
39.

4-Dimethylaminophenethylamine, a sensitive, specific, electrochemically detectable monoamine oxidase-B substrate.

Reyes-Parada M, Scorza MC, Silveira R, Dajas F, Cassels BK.

Life Sci. 1994;54(25):1955-63.

PMID:
8201844

Supplemental Content

Loading ...
Support Center